Role of P-glycoprotein in Drug Interactions

P-glycoprotein Basics - The Cellular Bouncer

• P-glycoprotein (P-gp) is an ATP-dependent efflux transporter protein.
• Acts as a "cellular bouncer," actively pumping diverse xenobiotics (especially drugs) out of cells.
• Major physiological sites and functions:
  • Intestine: Limits oral drug absorption (↓ bioavailability).
  • Blood-Brain Barrier (BBB): Restricts drug entry into the CNS.
  • Kidney (renal tubules): Promotes drug excretion into urine.
  • Liver (hepatocytes): Facilitates biliary drug excretion.
  • Placenta: Protects the fetus from harmful substances.
• Overall effect: Reduces systemic drug exposure, protects vital organs.

⭐ P-gp is encoded by the ABCB1 gene (formerly MDR1 gene) and plays a key role in multi-drug resistance in cancer cells.

P-gp Mechanism & PK Impact - The Gatekeeper's Action

• P-glycoprotein (P-gp): ATP-dependent efflux pump (MDR1 gene product).
• Mechanism: Actively transports drugs out of cells via ATP hydrolysis.
  • Reduces intracellular drug levels.
• PK Impact & Locations:
  • Intestine: ↓ Drug absorption → ↓ oral bioavailability.
  • Blood-Brain Barrier (BBB): ↓ CNS drug penetration.
  • Kidney/Liver: ↑ Drug excretion.
  • Placenta: Limits fetal drug exposure.
  • Cancer cells: Contributes to multidrug resistance.

⭐ P-gp utilizes ATP hydrolysis to actively efflux a wide range of structurally diverse drugs, impacting their bioavailability and tissue distribution.

P-gp Drug Interactions - The Traffic Control

• P-glycoprotein (P-gp, MDR1): Efflux pump (ATP-dependent) in intestines, BBB, kidney, liver.
• Function: ↓ Drug absorption & CNS entry; ↑ drug elimination.
• Modulation causes significant Drug-Drug Interactions (DDIs) & affects drug efficacy/toxicity.

⭐ Co-administration of a P-gp inhibitor (e.g., verapamil) with a P-gp substrate (e.g., digoxin) can significantly increase the substrate's plasma concentration and risk of toxicity.

Clinical & Genetic Aspects - P-gp in Practice

• Drug Resistance:
  • Cancer: P-gp overexpression → Multi-Drug Resistance (MDR) → ↓chemo efficacy (e.g., doxorubicin).
  • Infections: Resistance to HIV PIs, antifungals.
• Altered Drug Efficacy & Toxicity:
  • Variable P-gp expression → altered oral drug bioavailability (digoxin, dabigatran) → ↑toxicity or ↓efficacy.
  • Affects CNS drug penetration (e.g., loperamide).
• Genetic Factors:

  ⭐ Genetic polymorphisms in the ABCB1 gene (encodes P-gp) can lead to variable P-gp expression or activity, contributing to inter-individual differences in drug efficacy and toxicity for P-gp substrates.

  • SNPs in ABCB1 → altered P-gp function → variable response (e.g., tacrolimus, cyclosporine).
• Therapeutic Implications:
  • Dose adjustments for P-gp substrates/inhibitors/inducers.
  • P-gp inhibitors (verapamil, quinidine) to overcome MDR or ↑drug absorption.

High‑Yield Points - ⚡ Biggest Takeaways

• P-glycoprotein (P-gp): an efflux pump (ABCB1/MDR1 gene); limits drug absorption & distribution.
• Locations: intestine, liver, kidney, Blood-Brain Barrier (BBB), placenta; pumps drugs out of cells.
• Key P-gp substrates: digoxin, dabigatran, cyclosporine, vinca alkaloids, loperamide.
• P-gp Inducers (e.g., rifampicin, St. John's Wort): ↓ substrate levels → risk of therapeutic failure.
• P-gp Inhibitors (e.g., verapamil, ketoconazole, ritonavir): ↑ substrate levels → risk of toxicity.
• ABCB1 genetic polymorphisms alter P-gp function, affecting individual drug response and toxicity.
• Crucial in Drug-Drug Interactions (DDIs), especially for narrow therapeutic index drugs like digoxin and tacrolimus.